Aura (AURA) Chief People Officer Julie Receives RSU and Option Awards

What Happened

• Julie, Aura Biosciences' Chief People Officer, was awarded 107,611 restricted stock units (RSUs) and 212,389 derivative awards (stock options) on 2026-09-01. Both grants are reported at $0.00 (the awards themselves required no cash outlay by the insider).

Key Details

• Transaction date: 2026-09-01; reported same day (filing dated 2026-09-01).
• RSUs: 107,611 units; each RSU equals the right to receive one share of common stock (F1). Vesting: four substantially equal annual installments; first tranche scheduled to vest on September 15, 2027 (subject to continued service).
• Options/Derivative: 212,389 units reported as a derivative award (F2). Vesting: 25% vest on August 12, 2027, with the remainder vesting pro‑rata over 36 monthly installments thereafter (subject to continued service).
• Price reported: $0.00 for both grants (standard for equity awards/grants); filing does not state strike price or current outstanding shares owned after the grants in the excerpt provided.
• Footnotes: F1 = inducement RSU award; F2 = option vesting schedule. No 10b5-1 plan, tax withholding, or late-filing note indicated in the provided filing.

Context

• These are compensation/inducement awards, not open‑market purchases or sales. RSUs convert to shares upon vesting (one-for-one), while the derivative award represents options that must vest before they can be exercised. Such grants are commonly used for hiring/retention and do not by themselves signal immediate stock purchases or sales.